These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25859553)

  • 1. SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma.
    Blanco VM; Curry R; Qi X
    Oncoscience; 2015; 2(2):102-110. PubMed ID: 25859553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles.
    Davis HW; Vallabhapurapu SD; Chu Z; Wyder MA; Greis KD; Fannin V; Sun Y; Desai PB; Pak KY; Gray BD; Qi X
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.
    Kaynak A; Davis HW; Vallabhapurapu SD; Pak KY; Gray BD; Qi X
    Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.
    Blanco VM; Chu Z; Vallabhapurapu SD; Sulaiman MK; Kendler A; Rixe O; Warnick RE; Franco RS; Qi X
    Oncotarget; 2014 Aug; 5(16):7105-18. PubMed ID: 25051370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
    Wojton J; Chu Z; Mathsyaraja H; Meisen WH; Denton N; Kwon CH; Chow LM; Palascak M; Franco R; Bourdeau T; Thornton S; Ostrowski MC; Kaur B; Qi X
    Mol Ther; 2013 Aug; 21(8):1517-25. PubMed ID: 23732993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine.
    Winter PM; Pearce J; Chu Z; McPherson CM; Takigiku R; Lee JH; Qi X
    J Magn Reson Imaging; 2015 Apr; 41(4):1079-87. PubMed ID: 24797437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.
    Chu Z; Abu-Baker S; Palascak MB; Ahmad SA; Franco RS; Qi X
    PLoS One; 2013; 8(10):e75507. PubMed ID: 24124494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of cancer cells using SapC-DOPS nanovesicles.
    Davis HW; Hussain N; Qi X
    Mol Cancer; 2016 May; 15(1):33. PubMed ID: 27160923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SapC-DOPS nanovesicles as targeted therapy for lung cancer.
    Zhao S; Chu Z; Blanco VM; Nie Y; Hou Y; Qi X
    Mol Cancer Ther; 2015 Feb; 14(2):491-8. PubMed ID: 25670331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
    Wojton J; Meisen WH; Jacob NK; Thorne AH; Hardcastle J; Denton N; Chu Z; Dmitrieva N; Marsh R; Van Meir EG; Kwon CH; Chakravarti A; Qi X; Kaur B
    Oncotarget; 2014 Oct; 5(20):9703-9. PubMed ID: 25210852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SapC-DOPS - a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy.
    N'Guessan KF; Patel PH; Qi X
    Cell Commun Signal; 2020 Jan; 18(1):6. PubMed ID: 31918715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saposin C coupled lipid nanovesicles specifically target arthritic mouse joints for optical imaging of disease severity.
    Qi X; Flick MJ; Frederick M; Chu Z; Mason R; DeLay M; Thornton S
    PLoS One; 2012; 7(3):e33966. PubMed ID: 22470501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas.
    Sulaiman MK; Chu Z; Blanco VM; Vallabhapurapu SD; Franco RS; Qi X
    Mol Cancer; 2015 Apr; 14():78. PubMed ID: 25889084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease.
    Sun Y; Liou B; Chu Z; Fannin V; Blackwood R; Peng Y; Grabowski GA; Davis HW; Qi X
    EBioMedicine; 2020 May; 55():102735. PubMed ID: 32279952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles.
    Blanco VM; Chu Z; LaSance K; Gray BD; Pak KY; Rider T; Greis KD; Qi X
    Oncotarget; 2016 May; 7(22):32866-75. PubMed ID: 27096954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer: current standards, working towards a new therapeutic approach.
    Olowokure O; Qi X
    Expert Rev Anticancer Ther; 2014 May; 14(5):495-7. PubMed ID: 24621210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity and Selectivity in Skin Cancer by SapC-DOPS Nanovesicles.
    Abu-Baker S; Chu Z; Stevens AM; Li J; Qi X
    J Cancer Ther; 2012 Aug; 3(4):321-326. PubMed ID: 25485166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.
    N'Guessan KF; Davis HW; Chu Z; Vallabhapurapu SD; Lewis CS; Franco RS; Olowokure O; Ahmad SA; Yeh JJ; Bogdanov VY; Qi X
    Mol Ther; 2020 Aug; 28(8):1876-1886. PubMed ID: 32516572
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.